Nektar Therapeutics (NKTR) stock forecast and price target
Price $37.27 · data as of November 13, 2026
12-month price target
Average target$131.92
Upside / downside+253.9%
Analysts12
ConsensusBuy
Low $40.00Average $131.92High $192.00
Gold marker: average target · white marker: today’s price ($37.27)
Analyst ratings
Strong buy 1Buy 10Hold 4Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-7.21 | +17.0% | $41M |
| Next fiscal year ends December 31, 2027 | $-9.80 | −38.1% | $51M |
| Next quarter ends December 31, 2026 | $-2.41 | −90.7% | $9M |
| Quarter after ends March 31, 2027 | $-2.51 | −38.2% | $9M |
Consensus of the analysts covering Nektar Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.
Frequently asked questions
What is the Nektar Therapeutics stock price target?
The average 12-month target from 12 analysts is $131.92, 253.9% above the current price of $37.27 Targets range from $40.00 to $192.00.
Is Nektar Therapeutics a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 10 buy, 4 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Nektar Therapeutics expected to earn?
Analysts expect EPS of $-7.21 for the fiscal year ending December 31, 2026 and $-9.80 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.